PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.27

Change

-0.07 (-5.22)%

Market Cap

N/A

Volume

1.40M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-7.37 (-1.68%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.47 (-0.26%)

USD 65.38B
ARGX argenx NV ADR

-18.43 (-3.29%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

-3.33 (-1.23%)

USD 32.75B
SMMT Summit Therapeutics PLC

-0.65 (-2.57%)

USD 27.07B
ONC BeiGene, Ltd.

-8.52 (-3.65%)

USD 26.35B
RPRX Royalty Pharma Plc

-0.53 (-1.59%)

USD 18.40B
INSM Insmed Inc

-2.04 (-3.01%)

USD 11.84B
INCY Incyte Corporation

-0.04 (-0.07%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-1.59 (-2.59%)

USD 11.29B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.51% 17% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.51% 17% F 8% B-
Trailing 12 Months  
Capital Gain -80.93% 19% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.93% 19% F 7% C-
Trailing 5 Years  
Capital Gain -93.72% 31% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.72% 31% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -29.45% 15% F 8% B-
Dividend Return -29.45% 15% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.65% 89% A- 63% D
Risk Adjusted Return -106.51% 8% B- 3% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector